Johnson & Johnson

News & Events

Press Releases

In The Media

1. Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

   Business Wire JUL 30, 2025 4:32 PM EDT
   Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23 rd Annual Global Heal...
   READ ARTICLE

2. Johnson & Johnson Launches VIRTUGUIDE(TM) AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

   PR Newswire JUL 29, 2025 8:03 AM EDT
   Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U....
   READ ARTICLE

3. Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis

   PR Newswire JUL 29, 2025 8:00 AM EDT
   Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) l...
   READ ARTICLE

4. Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare Conference

   Business Wire JUL 24, 2025 4:30 PM EDT
   Johnson & Johnson (NYSE: JNJ) will present at the 2025 Wells Fargo Healthcare Conference on W...
   READ ARTICLE

5. Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

   Canada Newswire JUL 22, 2025 8:45 AM EDT
   Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar ...
   READ ARTICLE

6. Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

   PR Newswire JUL 22, 2025 8:45 AM EDT
   Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar ...
   READ ARTICLE

7. Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis

   PR Newswire JUL 21, 2025 8:00 AM EDT
   Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment...
   READ ARTICLE

8. Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

   PR Newswire JUL 17, 2025 8:00 AM EDT
   Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle i...
   READ ARTICLE

9. Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

   Business Wire JUL 16, 2025 6:25 AM EDT
   Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash...
   READ ARTICLE

10. Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

    Business Wire JUL 16, 2025 6:20 AM EDT
    2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6...
    READ ARTICLE